{Reference Type}: Journal Article
{Title}: [Discovery of a New Siderophore Cephalosporin, Cefiderocol].
{Author}: Yamano Y;
{Journal}: Yakugaku Zasshi
{Volume}: 144
{Issue}: 6
{Year}: 2024
{Factor}: 0.314
{DOI}: 10.1248/yakushi.23-00197-1
{Abstract}: Cefiderocol is a novel siderophore-conjugated cephalosporin with a catechol residue acting as an iron chelator. Cefiderocol forms a chelating complex with ferric iron and is transported rapidly into bacterial cells through iron-uptake systems. As a result, cefiderocol shows good activity against Gram-negative bacteria, including carbapenem-resistant isolates that are causing significant global health issues. Cefiderocol has been approved for clinical use in the United States and Europe, where it is being used to treat infection caused by carbapenem-resistant Gram-negative pathogens.